How To Prevent GVHD in Allogenic HSCT?

By Blood Cancer Talks - Last Updated: January 24, 2024

In the latest episode of Blood Cancer Talks, Shernan Holtan, MD, of the University of Minnesota, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD; for a conversation on graft versus host disease (GVHD) prophylaxis in allogenic hematopoietic stem cell transplantation (HSCT).

Dr. Holtan and the hosts explored recent data on post-transplant cyclophosphamide and abatacept, including the BMT CTN 1203 trial. This trial studied three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for the prevention of GVHD with allogenic HSCT.

Another key trial discussed was BMT CTN 1703, which studied experimental prophylaxis (tacrolimus, mycophenolate mofetil, and cyclophosphamide) versus standard prophylaxis (tacrolimus plus methotrexate).

This podcast originally appeared on Blood Cancer Talks. 

Editorial Board